H. pylori—testing and treatment consensus

BreathTek UBT aligns with guideline recommendations from ACG, AAFP,  and Maastricht V/Florence Consensus Report to test for H. pylori in patients with uninvestigated  dyspepsia.1-3

Abbreviations: ACG, American College of Gastroenterology; AAFP, American Academy of Family Physicians.

ACG guidelines recommend a test-and-treat strategy to confirm eradication of H. pylori infection using UBT, fecal antigen test, and endoscopy methods.2

  • Test to detect the underlying cause of the condition
  • Treat the patient if infection is detected
  • Test again to confirm eradication at least 4 weeks after completing treatment

The test-and-treat strategy is recommended for patients who are under the age of 60 years and have no "alarm features."

  • Alarm features include bleeding, anemia, early satiety, unexplained weight loss, progressive dysphagia, odynophagia, recurrent vomiting, family history of GI cancer, and previous esophagogastric malignancy2

H. pylori testing should be performed by a test of active infection (13C-urea breath test or stool antigen test).4

  • Ables AZ, Simon I, Melton ER. Update on Helicobacter pylori treatment. Am Fam Physician. 2007;75(3):351-358.
  • Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-238. Accessed August 21, 2017.
  • Malfertheiner P, Megraud F, O’Morain CA, et al; European Helicobacter Study Group. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2016;0:1-25. doi:10.1136/gutjnl-2016-312288.
  • Talley NJ; American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005;129(5):1753-1755.